Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of proprietary patented drug-delivery platform DehydraTECH(TM), recently released partial results from human clinical study HYPER-H21-1. The study evaluated DehydraTECH-processed cannabidiol (“CBD”) for potential application against hypertension/high blood pressure. “The partial results showed that blood pressure was reduced across both male and female volunteers; it was more pronounced … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure”
Lexaria just released the most important results yet from its ongoing HYPER-H21-2 human clinical trials on the effects of the company’s patented DehydraTECH(TM)-processed CBD on blood pressure Chris Bunka, Lexaria’s CEO, termed the results as “statistically significant” Participants in the study reported up to an average 23% decrease in blood pressure and a 7% drop … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Draws Closer to NDA Filing for DehydraTECH CBD”
Related Editorial Hypertension, or high blood pressure, is rampant in America. An estimated 45% of adults in the United States, or 108 million people, have hypertension, yet only about one out of every four have their condition under control. That’s a big problem considering hypertension increases risks for heart disease and stroke, which are, respectively, … Continue reading “NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leading Out in Innovation of Hypertension Treatment”
Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology”
Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients The … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials”
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its CEO and Chairman Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The event is slated to take place virtually from Sept. 13-15, 2021. According to the update, Bunka will provide an overview of … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Present at H.C. Wainwright 23rd Annual Global Investment Conference”
Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes The DehydraTECH … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference”
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it is formally beginning the process towards an Investigational New Drug (“IND”) application filing with the Food and Drug Administration (“FDA”). The IND filing is for Lexaria’s DehydraTECH-processed cannabidiol (“DehydraTECH-CBD”) as a prospective registered pharmaceutical treatment for hypertension. The company … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins IND-Enabling Program for DehydraTECH-CBD for Hypertension”
Lexaria Bioscience Corp. and its patented DehydraTECH technology promote a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing DehydraTECH is sub-licensed to other companies in select countries, and is in close collaboration with the largest R&D organization in Canada, the National Research Council, since … Continue reading “Lexaria Bioscience Corp. (NASDAQ: LEXX) is Changing Absorption of Fat-Soluble Compounds Through Patented DehydraTECH(TM) Technology”
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to placebo. According to the announcement, partial results are being released today with additional blood pressure subset analyses, sleep … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results of Human Clinical Study Showing Effective, Safe BP Reduction”
